Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 499-505

  McNaghten, A D ^a,c   Hanson, Debra L ^a   Dworkin, Mark S ^a,b   Jones, Jeffrey L ^a   Turner, Jane ^d   Wohl, Amy ^d   Cohn, David ^e   Davidson, Arthur ^e   Rietmeijer, Cornelius ^e   Gable, Julia ^f   Thompson, Melanie ^f   Broyles, Stephanie ^g   Morse, Anne ^g   Mokotoff, Eve ^h   Wotring, Linda ^h   Sackoff, Judy ⁱ   De los Angeles Gomez, Maria ^j   Hunter, Robert ^j   Otero, Jose ^j   Miranda, Sandra ^k   Melville, Sharon ^l   Odem, Sylvia ^l   Keiser, Philip ^m   McNeely, Wes ⁿ   Reynolds, Kaye ⁿ   Buskin, Susan ^o   Hopkins, Sharon ^o   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ILLINOIS DEPARTMENT OF PUBLIC HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES   (United States)

^e Denver Department of Health and Hospitals   (United States)

^f AIDS Research Consortium of Atlanta   (United States)

^g Louisiana Dept Hlth and Hospitals   (United States)

^h MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

ⁱ NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^j University Central del Caribe   (Puerto Rico)

^k Puerto Rico Department of Health   (Puerto Rico)

^l TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^m PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

ⁿ Department of Health ^*  (United States)

^o Seattle King Co Dept of Pub Hlth   (United States)

more..

Author keywords

Antiretroviral therapy; HAART prescription; Highly active antiretroviral therapy (HAART)

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ALCOHOLISM; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG INDICATION; ETHNOLOGY; FEMALE; GENDER; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RACE; SEXUAL BEHAVIOR; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037446439     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00006     Document Type: Article

References (46)

1. Centers for Disease Control. Update: trends in AIDS incidence, deaths, and prevalence-United States, 1996. MMWR. 1997;46: 165-173.
2. Centers for Disease Control. Update: trends in AIDS incidence-United States, 1996. MMWR. 1997;46:861-867.
3. McNaghten AD, Hanson DL, Jones JL, et al. Effects of antiretroviraltherapy and opportunistic chemoprophylaxis on survival after AIDS diagnosis. AIDS. 1999;13:1687-1695.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
7. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334:1011-1017.
8. Deeks SG, Smith M, Holodniy M, et al. HIV protease inhibitors: a review for clinicians. JAMA. 1997;277:145-153.
9. Condra JH. Resistance to HIV protease inhibitors. Haemophilia. 1998;4:610-615.
10. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulations of mutations in HIV-1 protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
11. Condra JH, Shielf WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
12. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
13. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV cohort study. AIDS. 1999;13:2547-2554.
14. Fairfield KM, Libman H, Davis RB, et al. Delays in protease inhibitor use in clinical practice. J Gen Int Med. 1999;14:395-401.
15. Centers for Disease Control. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR. 1998; 47(No. RR-5):42-82.
16. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. BETA. 1997;11-22.
17. Farizo KM, Buehler JW, Chamberland ME, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA. 1992;267:1798-1805.
18. Dworkin MS, Wan PCT, Hanson DL, et al. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus infected patients in the protease inhibitor era. J Infect Dis. 1999;180:621-625.
19. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41(No. RR-17).
20. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA. 1998;280: 78-86.
21. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277: 1962-1969.
22. Carpenter CJ, Cooper, DA, Fischl MA, et al. Antiretroviral therapy for in adults: updated recommendations of the international AIDS society-USA panel. JAMA. 2000;283:381-390.
23. Centers for Disease Control. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR. 1998;47(No. RR-5):42-82. Updated as the living document February 2001 on the HIV/AIDS Treatment web site, www.hivatis. org.
24. Stone V, Steger KA, Hirschhorn LR, et al. Access to treatment with protease inhibitor (PI) containing regimens: is it equal for all [abstract 42305]? Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
25. Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. Health Serv Res. 2000;2:389-416.
26. Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv Res. 1999;34(1 Pt 1):123-144.
27. Blair J, Hanson D, Jones J, et al. Do gender differences in viral load predict differences in HIV disease progression [abstract 195]? Presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000.
28. Diamond I. Alcoholism and alcohol abuse. In Wyngaaden JB, Smith LH Jr, Bennett JC. Cecil textbook of medicine, 19th ed. Philadelphia: WB Saunders; 1992:44-47.
29. Odem S, Sorvillo F, Kerndt P, et al. The prescription of protease inhibitors among women with AIDS in Los Angeles County [abstract 304.5]. Presented at the National Conference on Women & HIV, Los Angeles, May 4-7, 1997.
30. Sorvillo F, Kerndt P, Odem S, et al. Use of protease inhibitors among persons with AIDS in Los Angeles County. AIDS Care. 1999;11:147-155.
31. McNaghten A, Hanson D, Dworkin M, et al., Adult/Adolescent Spectrum of HIV Disease Project Group. Inequities between gender and racial groups in prescription of highly active antiretroviral therapy [abstract ThPeB5286]. Presented at the 13th World AIDS Conference, Durban, South Africa, July 9-14, 2000.
32. Taber CW. In Thomas CL. Taber's cyclopedic medical dictionary, 17th ed. Philadelphia: FA Davis, 1989.
33. Tucker GJ. Psychiatric disorders in medical practice. In Wyngaaden JB, Smith LH Jr, Bennett JC. Cecil textbook of medicine, 19th ed. Philadelphia: WB Saunders, 1992:2080-2081.
34. Wilson T, Barren Y, Cohen M, et al. Prevalence and predictors of adherence to antiretroviral therapy (ART) among HIV+ women [abstract TuPp1199]. Presented at the 13th World AIDS Conference, Durban, South Africa, July 9-14, 2000.
35. Moore J, Hamburger M, Schoenbaum E, et al. Predictors of adherence to antiretroviral therapy among HIV-infected women [abstract WePeD4598]. Presented at the 13th World AIDS Conference, Durban, South Africa, July 9-14, 2000.
36. Starace F, DeGaetano A, Chirianni A, et al. Non-adherence in HIV-seropositive persons: psychosocial factors and implications for treatment [abstract TuOrD333]. Presented at the 13th World AIDS Conference, Durban, South Africa, July 9-14, 2000.
37. Montaner J, Hogg R, Yip B, et al. Predictors of compliance with triple combination therapy among HIV-positive men and women in British Columbia [abstract TuPpD1200]. Presented at the 13th World AIDS Conference, Durban, South Africa, July 9-14, 2000.
38. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug resistant HIV-1 variants. Lancet. 1999;354:729-733.
39. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-1149.
40. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
41. Hecht FM, Grant RM, Pertopoulos C, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
42. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychol. 1994;51:8-19.
43. Grant BF, Hartford TC, Dawson DA, et al. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Epidemiol Bull No. 35. Alcohol Health Res World. 1994;18:243-248.
44. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
45. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
46. Suh JS, Sepkowitz KA, Carrow M, et al. Patients declining [abstract 22342]? Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.